Wei Sang

16PUBLICATIONS
57CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMolecular targetsSocio-economic development
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 22, 2026
Long-term follow-up of third generation anti-CD30 CAR T-cell therapy in relapsed/refractory CD30+ lymphomas: a single-arm, multicentre, phase 1-2 trial.

|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary disease.

|Aug 23, 2025
Prognostic value of the co-stimulatory molecule OX40 expression in Extranodal Natural Killer/T-cell Lymphoma.

Haiyan Zhang, Yujie Li, Qing Zhang

|May 09, 2025
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study.

Si-Yuan Chen, Peng-Peng Xu, Ru Feng

|Mar 16, 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myeloma.

Sha Ma, Jieyun Xia, Miao Zhang

|Sep 09, 2024
Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021.

Ying Wang, Ziyuan Shen, Chenlu He

Pageof 3

Frequent Collaborators

4 joint publications

Kailin Xu

3 joint publications

Jiang Cao

3 joint publications

Feng Zhu

3 joint publications

Ziyuan Shen